BIOXCEL THERAPEUTICS INC (BTAI)
US09075P1057 - Common Stock
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies...
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN,...
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing...
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501...
Commit To Purchase BioXcel Therapeutics At $1.50, Earn 19.6% Annualized Using Options
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug...
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy.
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...
UBS cuts BioXcel to neutral; cites regulatory issues, financing (NASDAQ:BTAI)
UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
BioXcel Therapeutics announces termination of proposed public offering (NASDAQ:BTAI)
BioXcel Therapeutics terminates proposed public offering of $60 million in stock due to unfavorable market conditions.
BioXcel Therapeutics Announces Termination of Proposed Public Offering
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy...
Noteworthy Friday Option Activity: AI, AFRM, BTAI
Why Is CleanSpark (CLSK) Stock Up 27% Today?
CleanSpark stock is rising higher on Friday as investors in CLSK shares celebrate the company's positive Q1 earnings report.
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
BioXcel Therapeutics stock is falling on Friday after the company announced plans for a proposed public offering of BTAI shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!